Matches in Nanopublications for { ?s ?p "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 14 of
14
with 100 items per page.
- NP522718.RA7VGpARxhaDRc6iu0CW40EkqFSkTrmvX8Cu1TJw0_ABw130_assertion description "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP522718.RA7VGpARxhaDRc6iu0CW40EkqFSkTrmvX8Cu1TJw0_ABw130_provenance.
- NP389533.RAGuU1kkzNUSw_qzC67wMoEUBtl3GlKhB9v2zmAh_kF2E130_assertion description "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP389533.RAGuU1kkzNUSw_qzC67wMoEUBtl3GlKhB9v2zmAh_kF2E130_provenance.
- NP543986.RAU-OfJZzMqM0kXs2yd5fPMrOgLmUDuoeoD07OXw88jiw130_assertion description "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP543986.RAU-OfJZzMqM0kXs2yd5fPMrOgLmUDuoeoD07OXw88jiw130_provenance.
- assertion description "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP786334.RAWswdZgf90ZPKUAmVvR8AeI82pQgGqFcmbXsCfXPO5O4130_assertion description "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP786334.RAWswdZgf90ZPKUAmVvR8AeI82pQgGqFcmbXsCfXPO5O4130_provenance.
- NP786335.RAZW-vifyhPoWuTme7grndDFsSp2nbh_-grTkb2BB2CJQ130_assertion description "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP786335.RAZW-vifyhPoWuTme7grndDFsSp2nbh_-grTkb2BB2CJQ130_provenance.
- assertion description "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP544299.RAPNsmSphXzzhNVVChMjYLtEna13FhcbgAD3txsQaVCyo130_assertion description "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP544299.RAPNsmSphXzzhNVVChMjYLtEna13FhcbgAD3txsQaVCyo130_provenance.
- NP965427.RAMUbmyGxw6n1S5JJdWWGUYgv6dRMru4nNECr54uPYyOU130_assertion description "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP965427.RAMUbmyGxw6n1S5JJdWWGUYgv6dRMru4nNECr54uPYyOU130_provenance.
- NP786333.RAPQ6XbDcy2xcjScGNGihqJcC0Va4SS_0_qqfaHKMYxHo130_assertion description "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP786333.RAPQ6XbDcy2xcjScGNGihqJcC0Va4SS_0_qqfaHKMYxHo130_provenance.
- NP965407.RA08PvHBsgXKHuNhJewPsNWleXLpUivttEJuWQ-ZqRFkw130_assertion description "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP965407.RA08PvHBsgXKHuNhJewPsNWleXLpUivttEJuWQ-ZqRFkw130_provenance.
- NP786331.RA30ndEGsQVIE2UJ_UNTqys4_ytykZvBIyB6E9PpLDGlk130_assertion description "[Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP786331.RA30ndEGsQVIE2UJ_UNTqys4_ytykZvBIyB6E9PpLDGlk130_provenance.